Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

Infection

Volumn 43, Issue 3, 2015, Pages 277-286

  Cucchetto, G ^a   Cazzadori, A ^a   Conti, M ^a   Cascio, G L ^a   Braggio, P ^b   Concia, E ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Istituto di Medicina Nucleare AOUI   (Italy)

Author keywords

Aspergillosis; Aspergillus fumigatus; Lung disease; Triazole; Voriconazole

Indexed keywords

FLUORODEOXYGLUCOSE F 18; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ALCOHOLISM; ANOREXIA; ARTICLE; ASPERGILLUS; ASTHMA; BRONCHIAL ASPIRATION PROCEDURE; CHEMORADIOTHERAPY; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PANCREATITIS; CHRONIC PULMONARY ASPERGILLOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COUGHING; CYSTIC PULMONARY DYSPLASIA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPLASIA; ENDOTRACHEAL PROSTHESIS; FEMALE; FEVER; HALLUCINATION; HEMOPTYSIS; HUMAN; IMMUNE DEFICIENCY; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG CARCINOMA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTHESIS; RETROSPECTIVE STUDY; SKIN TOXICITY; SMOKING; SPUTUM; THORAX RADIOGRAPHY; TRACHEOSTOMY PROSTHESIS; TREATMENT DURATION; TUBERCULOSIS; WEIGHT REDUCTION; YOUNG ADULT; LONGITUDINAL STUDY; ORAL DRUG ADMINISTRATION; PULMONARY ASPERGILLOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY ASPERGILLOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VORICONAZOLE; YOUNG ADULT;

EID: 84930272209     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0711-4     Document Type: Article

References (39)

1. Segal BH. Aspergillosis. N Engl J Med. 2009;360:1870–84.
2. Chotirmall SH, Al-Alawi M, Mirkovic B, et al. Aspergillus-associated airway disease, inflammation and the innate immune response. Biomed Res Int. 2013. doi:10.1155/2013/723129.
3. Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;156–74.
4. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis. 2003;37:S265–80.
5. Izumikawa K, Takazono T, Kohno S. Chronic aspergillus infections of the respiratory tract: diagnosis, management and antifungal resistance. Curr Opin Infect Dis. 2010;23:584–9.
6. Izumikawa K, Tashiro T, Tashiro M, et al. Pathogenesis and clinical features of chronic pulmonary aspergillosis—is it possible to distinguish CNPA and CCPA clinically? J Infect Chemother. 2014;20:208–12.
7. Tashiro T, Izumikawa K, Tashiro M. A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis. 2013;66:312–6.
8. Farid S, Mohamed S, Devbhandari M. Results of surgery for chronic pulmonary aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence—A National Centre’s experience. J Cardiothorac Surg. 2013;8:180.
9. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.
10. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax. 1983;38:572–8.
11. Nam HS, Jeon K, Um SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis. 2010;14:e479–82.
12. Nakamoto K, Takayanagi N, Kanauchi T, et al. Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med. 2013;52:727–34.
13. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96–128.
14. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med. 2006;119:e17–24.
15. Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010;61:410–8.
16. Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 2012;31:3231–9.
17. Saito T, Fujiuchi S, Sasaki Y, et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection. 2012;40:661–7.
18. Al-shair K, Atherton GT, Harris C, et al. Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis. 2013;57:828–35.
19. SmPC voriconazole. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000387/WC500049756.pdf.
20. Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010;51:1383–91.
21. Barton RC, Hobson RP, McLoughlin H, Morris A, Datta B. Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria. Eur J Clin Microbiol Infect Dis. 2013;32:923–8.
22. Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest. 2007;131:1435–41.
23. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J. 2011;37:865–72.
24. Camara B, Reymond E, Saint-Raymond C, et al. Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry. Clin Respir J. 2014. doi:10.1111/crj.12105.
25. Jhun BW, Jeon K, Eom JS, et al. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol. 2013;518:811–7.
26. Gargani Y, Bishop P, Denning DW. Too many mouldy joints—marijuana and chronic pulmonary aspergillosis. Mediterr J Hematol Infect Dis. 2011;3:e2011005.
27. Cescon DW, Page AV, Richardson S, et al. Invasive pulmonary aspergillosis associated with marijuana use in man with colorectal cancer. J Clin Oncol. 2008;2613:2214–5.
28. Verweij PE, Kerremans JJ, Voss A, Meis JF. Fungal contamination of tobacco and marijuana. JAMA. 2000;284:2875.
29. Zmeili OS, Soubani AO. Pulmonary aspergillosis: a clinical update. QJM. 2007;100:317–34.
30. Kitasato Y, Tao Y, Hoshino T, et al. Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology. 2009;14:701–8.
31. Hachem RY, Kontoyiannis DP, Chemaly RF, et al. Utility of galactomannan enzyme immunoassay and (1,3)beta-d-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol. 2009;47:129–33.
32. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–27.
33. Kono Y, Tsushima K, Yamaguchi K, et al. The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis. Respir Med. 2013;107:1094–100.
34. Shin B, Koh WJ, Jeong BH, et al. Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis. J Infect. 2014;68:494–9.
35. Ellis M, Al-Ramadi B, Finkelman M, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57:287–95.
36. 18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409–17.
37. Baxter CG, Bishop P, Low SE, Baiden-Amissah K, Denning DW. Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax. 2011;66:638–40.
38. Baliko Z, Sarosi V, Illes MB, et al. PET-CT imaging and reality. Pathol Oncol Res. 2011;17:393–5.
39. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123–9.